Outcomes and predictors of treatment failure following two-stage total joint arthroplasty with articulating spacers for evolutive septic arthritis

• Published in: BMC musculoskeletal disorders Vol. 20; no. 1; p. 272
• Main Authors: Xu, Chi, Kuo, Feng-Chih, Kheir, Matthew, Li, Xin, Chai, Wei, Chen, Ji-Ying
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.06.2019; BioMed Central; BMC
• Subjects: Analysis; Antiarthritic agents; Antibiotics; Arthritis; Arthroplasty; Blood tests; C-reactive protein; Cardiovascular disease; Care and treatment; Cement; Control; Cytokines; Diabetes; Erythrocyte sedimentation rate; Hip; Infection; Infectious arthritis; Interleukin 6; Interleukins; Joint diseases; Joint surgery; Knee; Laboratories; Medical research; Musculoskeletal diseases; Organisms; Orthopedic surgery; Outcome and process assessment (Medical care); Patients; Performance evaluation; Prostheses; Prostheses and implants; Prosthetics; Risk factors; Septic arthritis; Spacer; Staphylococcus infections; Success; Surgery; Survival; Systematic review; Total joint arthroplasty; Germany; C-reactive protein; Erythrocyte sedimentation rate; Total joint arthroplasty; Septic arthritis; Interleukin-6
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-019-2652-7

The treatment strategy for evolutive septic arthritis (SA) with coexistent degenerative joint disease is not well established. The purposes of this study were to 1) investigate treatment outcome and potential risk factors of treatment failure in patients with evolutive SA following two-stage procedure, including insertion of an antibiotic-loaded spacer at the first stage and subsequent implantation of a new prosthesis; and 2) determine the performance of serum erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Interleukin-6 (IL-6) in predicting persisting infection at second-stage procedure. We retrospectively reviewed 74 patients with evolutive SA of hips and knees who underwent a two-stage TJA between 2008 and 2015. The treatment success was defined according to the modified Delphi criteria and Kaplan-Meier survivorship curves were constructed to determine treatment success. A Cox regression model was performed to identify risk factors for treatment failure. Receiver operating characteristic (ROC) curves were generated to determine the prognostic value of ESR, CRP, and IL-6 in predicting persistent infection before second-stage prostheses implantation. Overall, the treatment success rate was 93% for hips and 100% for knees after the first-stage surgery. The treatment success rate was 89% for hips and 84% for knees after second-stage prosthesis implantation with a mean follow-up of 4.7 (range, 2.2 to 10.8) years. Older age (Hazard ratio [HR] [per 10-year increase], 1.20; 95% confidential interval [CI], 1.11 to 1.62), higher preoperative CRP level (HR [per 1-mg/dL increase], 1.15; 95% CI, 1.04 to 1.28) and resistant organism (HR, 13.96; 95% CI, 3.29 to 19.20) were associated with an increased risk of treatment failure. All serologic tests presented limited values in predicting persisting infection, with the area under ROC curve of ESR, CRP, IL-6 and combination of the three markers was 57.8, 61.6, 60.3, and 62.1%, respectively. Two-stage TJA is an adequate management of infection control in patients with evolutive SA. The three potential risk factors (old age, high preoperative CRP, and resistant organism profile) may predict treatment failure following a two-stage procedure for evolutive SA. Additionally, serum ESR, CRP, and IL-6 had no benefit in predicting persisting infection before second-stage prostheses implantation. These findings may be useful when treating patients with evolutive SA.